Mass-DAC
The Massachusetts Data Analysis Center (Mass-DAC)
was a data-coordination center active 2002 through 2017, in response to a state mandate, provides expert evaluation of cardiac surgery and angioplasty data in the Commonwealth of Massachusetts. Mass-DAC collected and validated patient-specific clinical data from all Massachusetts hospitals that provide cardiac surgery or percutaneous coronary interventions. This data was used to monitor the quality of cardiac care delivered in the Commonwealth to improve the level of care provided.
In appreciation for Dr. Normand's contributions as Director of Mass-DAC, she was honoured with the Outstanding Lifetime Achievement Award by the Council on Quality of Care and Outcomes Research (QCOR) of the American Heart Association (AHA) at the QCOR Annual Meeting in April 2017.
In 2012, Dr. Normand received the Distinguished Scientist award from the American Heart Association due to her national and international leadership in the development of innovative statistical methods for health services and outcomes research. John Rumsfeld MD, PhD, former QCOR chair, said:
“Normand has demonstrated leadership in her field, and the impact of her work has been far-reaching. Her unique combination of high-level scholarship, creativity and remarkable interpersonal skills has led her work to change the way investigators approach their own research. Without question, she is considered one of the preeminent biostatisticians in the country and is certainly among the most influential individuals in health services and outcomes research.”
Presentations
- Normand S-L. Limitations of Analyses in Continuous Quality Improvement: Accuracy. American College of Cardiology Scientific Sessions. March 2005.
- Stevens L. Coronary Artery Bypass Grafting after Uneventful Percutaneous Coronary Intervention in the Commonwealth of Massachusetts. American Heart Association Scientific Sessions, November 2007.
- Shapira O. The Association of Race and of Insurance with Utilization and Outcomes after Coronary Artery Bypass Grafting Surgery in Massachusetts. American Heart Association Scientific Sessions, November 2007.
- Mauri L. Long-Term Clinical Outcomes Following Drug-Eluting and Bare Metal Stenting in Massachusetts. American Heart Association Scientific Sessions, November 2007.
- Mauri L, Silbaugh TS, Garg P, Wolf RE, Zelevinsky K, Lovett A, Varma MR, Zhou Z, Normand S-LT. Long-Term Clinical Outcomes Following Drug-Eluting and Bare-Metal Stenting for Acute Myocardial Infarction in Massachusetts. American College of Cardiology Scientific Sessions, March 2008.
- Garg P, Normand S-LT, Silbaugh T, Wolf R, Zelevinsky K, Lovett A, Varma MR, Zhou Z, Mauri L. Drug-eluting or bare metal stenting in patients with diabetes mellitus: Results from the Mass-DAC registry. American Heart Association Scientific Sessions, November 2008.
- Sakhuja R, Silbaugh T, Varma M, Normand S-L, Mauri L. Drug-Eluting Stent Use in Acute Myocardial Infarction: Do Data Drive Practice? American College of Cardiology Scientific Sessions. March 2009.
- Barringhaus KG, Zelevinsky K, Lovett A, Normand S-L, Ho KKL. Impact of Independent Data Adjudication on Hospital-Specific Estimates of Risk-Adjusted Mortality Following Percutaneous Coronary Interventions in Massachusetts. American Heart Association Quality of Care and Outcomes Research Scientific Sessions. May 2009.
- Anis A, Normand S-L, Wolf RE, Lovett A, Mauri L, Patel N, and Jacobs AK. Outcomes Following Primary Percutaneous Coronary Intervention: A Comparison between Hospitals with and without Cardiac Surgery On-Site. American Heart Association Scientific Sessions. November 2009.
- Charytan DM, Varma MR, Silbaugh TS, Lovett AF, Normand S-LT, Mauri L. Long term Clinical Outcomes Following Drug-Eluting or Bare-Metal Stent Placement in Patients with Severely Reduced GFR: Results of the Massachusetts Data Analysis Center (Mass-DAC) State Registry. American Heart Association Scientific Sessions. November 2009.
- Khurana R. Independent US Validation of the British Columbia PCI Risk Score. American College of Cardiology Scientific Sessions. March 2010.
- Forman DE, Vasaiwala S, Silbaugh TS, Lovett A, Normand S-L, Mauri L. Acute and 3-year Bleeding Risks: Comparing Drug-Eluting to Bare-Metal Stents in Old and Very Old Adults in a Community Population. American Heart Association Scientific Sessions. November 2010.
- Yeh RW, Zelevinsky K, Normand S-LT, Sakhuja R, Lovett A, Weiner BH, Rosenfield KA. 30-Day All-Cause Readmission After Percutaneous Coronary Intervention in Massachusetts: Clinical Predictors and Hospital-Variation of a New Quality Metric. American Heart Association Scientific Sessions. November 2010.
- Ali MJ, Nedeljkovic ZS, Zelevinsky K, Lovett A, Normand S-LT, Jacobs AK. Mortality in STEMI Patients Undergoing Inter-Hospital Transfer for Primary PCI in Massachusetts. American Heart Association Scientific Sessions. November 2010.
- Albert MA, Silbaugh TS, Ayanian JZ, Lovett A, Wolf RE, Zelevinsky K, Resnic F, Normand S-LT. Impact of Massachusetts Health Care Reform on Racial, Ethnic, and Socioeconomic Disparities in Cardiovascular Care. American Heart Association Scientific Sessions. November 2010.
- Normand S-LT, Treacy S. Silbaugh, Zelevinsky K, Wolf RE, Cioffi M, Lovett A, Resnic FS, Ho KKL. Hospital Quality Following Percutaneous Coronary Intervention: Massachusetts Experience From 2003-2007. American Heart Association Scientific Sessions. November 2010.
- Kato NS, Cioffi M, Normand S-LT. Implantable Cardioverter Defibrillator Usage in the Commonwealth of Massachusetts – A 10 Year Study. American Heart Association Scientific Sessions. November 2010.
- Kato NS, Cioffi M, Normand S-LT. Unsupported Implantable Cardioverter Defibrillator Use in the Commonwealth of Massachusetts - 1997 to 2008. American Heart Association Scientific Sessions. November 2010.
- Cubeddu RJ, Lago RM, Zelevinsky K, Lovett AF, Mendoza I, Crane AM, Witzke CF, Normand S-LT, Pomerantsev E, Palacios IF. No Mortality Advantage of “On” versus “Off”-hours Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction: Results from the Massachusetts Data Analysis Center Registry. American Heart Association Scientific Sessions. November 2010.
- Normand S-LT, Silbaugh TS, Zelevinsky K, Wolf RE, Cioffi M, Lovett A, Resnic FS, Ho KKL. Hospital-quality Following Percutaneous Coronary Intervention: Massachusetts Experience From 2003-2007. American College of Cardiology Scientific Sessions. May 2010.
- Anis A, Normand S-LT, Wolf RE, Lovett A, Mauri L, Patel N, and Jacobs AK. Primary Percutaneous Coronary Intervention With or Without Cardiac Surgery On-Site: Massachusetts’ Experience. American Heart Association Scientific Sessions. November 2010.
- Yeh RW, Jones PG, Wolf RE, Normand S-LT, Cohen DJ, Ho KKL, Cutlip DE, Kugelmass AD, Spertus JA. Predicting the Restenosis Benefit of Drug-Eluting vs. Bare Metal Stenting Prior to Angiography: A Tool for Patients and Clinicians. American Heart Association Quality of Care and Outcomes Research Scientific Sessions. May 2010.
- Kato NS, Cioffi M, Normand S-LT. Internal Cardioverter Defibrillator Utilization in the Commonwealth of Massachusetts - 1997 to 2008. American College of Cardiology Scientific Sessions. March 2011.
- Vasaiwala S, Normand S-LT, Silbaugh TS, Forman D, Baron S, Lovett A, Mauri L. Impact of Completeness of Revascularization on Late Mortality in an Unrestricted Patient Population Undergoing Percutaneous Coronary Intervention with Drug-Eluting or Bare-Metal Stents. American Heart Association Quality of Care and Outcomes Research Scientific Sessions. May 2011.
- Forman D, Vasaiwala S, Silbaugh TS, Lovett A, Normand S-LT, Mauri L. Assessing utility of drug-eluting stents in coronary patients aged 85 years and older. American Heart Association Quality of Care and Outcomes Research Scientific Sessions. May 2011.
- Yeh RW, Normand S-LT, Mauri L, Wolf RE, Cohen DJ, Ho KKL, Spertus JA. Does the Expected Reduction in Restenosis from Drug-Eluting Stents Predict Actual Use? An Assessment of Treatment-Risk Paradox Using the C-statistic. American Heart Association Quality of Care and Outcomes Research Scientific Sessions. May 2011.
- Vasaiwala S, Forman D, Yeh RW, Silbaugh TS, Lovett A, Normand S-LT, and Mauri L. Selective Drug-Eluting Stent Use in Elderly Patients: Impact on Percutaneous Coronary Intervention Mortality and Bleeding Risk. American College of Cardiology Scientific Sessions. March 2012.
- Cubeddu R, Lago R, Zelevinsky K, Lovett A, Mendoza I, Crane A, Witzke C, Normand S-L, Pomerantsez E, Palacio I. No Mortality Advantage of “On” versus “Off”-hours Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction: Results from the Massachusetts Data Analysis Center Registry.
- Sarma A, Normand S-LT, Hatfield L, Matheny M, Resnic F. The Learning Curve for Medical Devices: Experience with Vascular Closure Devices in Massachusetts. American College of Cardiology Scientific Sessions. March 2013. American Heart Association Scientific Sessions. November 2012.
- Yeh RW, Mauri L, Wold R, Romm I, Lovett A, Normand S-L. Steep Declines in Population Rates of Coronary Revascularization. American Heart Association Scientific Sessions. November 2013.
- Yeh RW, Mauri L, Wolf RE, Romm IK, Biondolillo M, Lovett A, Normand S-LT. Steep Declines in Population Rates of Coronary Revascularization. American College of Cardiology Scientific Sessions. March 2014.
- Adhikari S, Normand S-L T. Non-parametric Bayesian Instrumental Variable Analysis: Comparing effectiveness of radial vs femoral arteries access Percutaneous Coronary Intervention (PCI) in reducing bleeding and vascular complications. EMR-IBS and Italian Region Conference. May 2017.